Loading…
Legislative Progress
Introduced
January 24, 2023
Latest Action
January 24, 2023
Primary Sponsor
Jenniffer González-ColónRepublican(PR)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
Medical Manufacturing, Economic Development, and Sustainability Act of 2023 or the MMEDS Act of 2023 This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical manufacturers. The bill increases the credit rate for minority businesses.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2024 · fourth_quarter · Utilities
Issues related to regulation of public utilities - no specific legislation. Issues related to support for transmission and transmission equipment manufacturing, including grid modernization technology - no specific legislation. Issues related to wildfire prevention, including Fire Safe Electrical Corridors Act, S. 2269, H.R. 6012 and inclusion of special use permits in various Farm Bill drafts. H.R.447 - To provide compensation flexibility to address retention and hiring issues at the Bonneville Power Administration. Issues related to Bonneville Power Administration retention, recruitment, and costs. Issues related to Harborton reliability project - no specific legislation.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Manufacturing
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · third_quarter · Manufacturing
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · second_quarter · Taxation/Internal Revenue Code
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · second_quarter · Manufacturing
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Taxation/Internal Revenue Code
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023) H.R.7024 - Tax Relief for American Families and Workers Act of 2024, specifically for provisions related to Title II, American Innovation and Growth
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · first_quarter · Manufacturing
H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023); General issues related to the manufacturing and supply chain resiliency of over-the-counter medications; Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation.
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Trade (domestic/foreign)
H.R. 133: MERIT Act H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 447: MMEDS Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 3858: No Free TRIPS Act S. 845: Short on Competition Act S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues WTO Trade Related Aspects of Intellectual Property - vaccine patents"
Client expense: $1,500,000 · Firm income: Not reported
2023 · fourth_quarter · Trade (domestic/foreign)
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 447: MMEDS Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 3858: No Free TRIPS Act S. 845: Short on Competition Act S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $6,430,000 · Firm income: Not reported
2023 · fourth_quarter · Taxation/Internal Revenue Code
Implementation of H.R. 3684, Infrastructure Investment and Jobs Act; General monitoring of Issues related to federal tax amortization of research and development expenses; General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses; General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA H.R.447 Medical Manufacturing, Economic Development, and Sustainability Act of 2023 (MMEDS Act of 2023)
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE